COVID-19 Tied to Progression of Chronic Liver Disease


TUESDAY, June 21, 2022 — About one in five patients with chronic liver disease (CLD) develop progressive cholestasis after severe COVID-19, according to a study published online May 21 in Hepatology.

Lukas Hartl, M.D., from University of Vienna, and colleagues examined the incidence of hepatic complications following severe COVID-19. The analysis included 496 hospitalized patients with COVID-19 (65 with preexisting liver disease).

The researchers found that COVID-19-related liver injury was more common among patients with CLD (24.6 versus 10.6 percent). Following severe COVID-19, CLD patients showed progressive cholestasis with persistently increasing levels of alkaline phosphatase and gamma-glutamyl transferase. Nearly one-fourth of patients with CLD (23.1 percent) developed cholestatic liver failure (cholestasis plus bilirubin ≥6 mg/dL) during COVID-19, and 15.4 percent of patients with CLD developed secondary sclerosing cholangitis (SSC), which was significantly more frequent with CLD and COVID-19 versus CLD patients with non-COVID-19 pneumonia. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis patients with metabolic risk factors accounted for most COVID-19-associated SSC. More than one-fourth of advanced CLD patients (26.3 percent) experienced hepatic decompensation following COVID-19.

“It is useful, in any case, to closely monitor liver function values in intensive care unit patients during or following COVID-19,” a coauthor said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

© 2022 HealthDay. All rights reserved.

Further Support and Information on COVID-19

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.



Source link

Published by Drugs.Com Know More. Be Sure
Managed by Pharma Enthusiast, To claim this account, mail us at pharmamedia.in@gmailcom
Get Connected!
Come and join Pharma Community. Expand your network in Pharma!

Comments

No comments yet